Johnson & Johnson (NYSE:JNJ) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,273,382 shares of the company's stock after selling 218,140 shares during the period. Johnson & Johnson comprises about 0.7% of New York State Common Retirement Fund's portfolio, making the stock its 20th largest position. New York State Common Retirement Fund owned approximately 0.14% of Johnson & Johnson worth $530,484,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Sloy Dahl & Holst LLC boosted its holdings in shares of Johnson & Johnson by 4.9% in the 1st quarter. Sloy Dahl & Holst LLC now owns 5,411 shares of the company's stock valued at $856,000 after buying an additional 255 shares in the last quarter. Azzad Asset Management Inc. ADV boosted its holdings in shares of Johnson & Johnson by 1.6% in the 1st quarter. Azzad Asset Management Inc. ADV now owns 45,840 shares of the company's stock valued at $7,251,000 after buying an additional 735 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of Johnson & Johnson by 22.0% in the 1st quarter. Sivia Capital Partners LLC now owns 4,606 shares of the company's stock valued at $729,000 after buying an additional 830 shares in the last quarter. Tradewinds Capital Management LLC boosted its stake in Johnson & Johnson by 3.3% in the 1st quarter. Tradewinds Capital Management LLC now owns 3,128 shares of the company's stock worth $495,000 after purchasing an additional 100 shares in the last quarter. Finally, OMNI 360 Wealth Inc. boosted its stake in Johnson & Johnson by 6.2% in the 1st quarter. OMNI 360 Wealth Inc. now owns 3,610 shares of the company's stock worth $571,000 after purchasing an additional 212 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Royal Bank of Canada lifted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Daiwa Capital Markets cut shares of Johnson & Johnson from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Finally, Citigroup lifted their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a "buy" rating in a research note on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $175.93.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $0.27 during trading on Friday, hitting $160.13. 5,256,652 shares of the stock traded hands, compared to its average volume of 5,957,264. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a market cap of $385.53 billion, a price-to-earnings ratio of 23.17, a P/E/G ratio of 2.84 and a beta of 0.52. The company has a fifty day moving average price of $163.31 and a two-hundred day moving average price of $155.51. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business's quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.66 EPS. As a group, equities analysts predict that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.10%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson's payout ratio is presently 71.78%.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company's stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.